Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17015986 | 0.94 | L3MBTL1 (0.33) | L3MBTL1LMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL17016007 | 0.89 | KDM4E (0.31) | L3MBTL1KDM4E | |
| SCHEMBL17016018 | 0.84 | KDM4E (0.35) | L3MBTL1KDM4E | |
| SCHEMBL17016009 | 0.84 | ESR1 (0.30) | L3MBTL1KDM4E | |
| SCHEMBL17015356 | 0.83 | MAOB (0.32) | LMNAALDH1A1 | |
| SCHEMBL17016070 | 0.82 | L3MBTL1 (0.32) | L3MBTL1LMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL17015200 | 0.82 | FGFR1 (0.31) | L3MBTL1KDM4E | |
| SCHEMBL17015825 | 0.82 | KDM4E (0.33) | L3MBTL1LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL17015669 | 0.82 | — | — | |
| SCHEMBL17016031 | 0.82 | KDM4E (0.44) | L3MBTL1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9837618-B2 | Compound and organic electroluminescence device including thesame | DOOSAN CORPORATION (KR) | 2017-12-05 | — | — | US | disclosed |
| US-9837618-B2 | Compound and organic electroluminescence device including thesame | DOOSAN CORPORATION (KR) | 2017-12-05 | — | — | US | disclosed |
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | DOOSAN CORPORATION (KR) | 2015-08-20 | — | — | US | disclosed |
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | DOOSAN CORPORATION (KR) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | INMT, IDO1, IDO2 | L3MBTL1 533/4885LMNA 2754/4885KDM4E 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.